News & Events

The Firm represented ZS Pharma, Inc. (“ZS Pharma”) in connection with a registered follow-on offering of common stock. ZS Pharma sold 4,015,939 shares of common stock in the offering for a total of approximately $185.7 million of gross proceeds to the company. The shares of ZS Pharma are listed on The Nasdaq Global Market under the ticker symbol “ZSPH.” J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC acted as joint bookrunning managers in the offering. BMO Capital Markets Corp., William Blair & Company, L.L.C. and LifeSci Capital LLC acted as co-managers in the offering.

ZS Pharma is a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. Its lead product candidate, ZS-9, has completed two Phase III clinical trials for the treatment of hyperkalemia.

The Simpson Thacher team included Kevin Kennedy, Diana Snyder and Stephanie Richards (Capital Markets); Judy Yan (Tax); Noah Leibowitz (Intellectual Property); and Jennie Getsin (Blue Sky).